Persistent maculopapular rash after the first dose of Pfizer‐BioNTech COVID‐19 vaccine

The ongoing global pandemic COVID‐19 led regulatory agencies to recently issue an emergency authorization for two effective Covid‐19 vaccines from Pfizer‐BioNTech and Moderna. Both vaccines use a novel technology of administering vaccination, namely a lipid nanoparticle‐formulated, nucleoside‐modifi...

Full description

Saved in:
Bibliographic Details
Published inJournal of the European Academy of Dermatology and Venereology Vol. 35; no. 7; pp. e423 - e425
Main Authors Ackerman, M., Henry, D., Finon, A., Binois, R., Esteve, E.
Format Journal Article Web Resource
LanguageEnglish
Published England John Wiley & Sons, Inc 01.07.2021
John Wiley and Sons Inc
Subjects
COVID-19 vaccines
Covid‐19 Special Forum
Letter To The Editor
Online AccessGet full text

Cover

More Information
Summary:The ongoing global pandemic COVID‐19 led regulatory agencies to recently issue an emergency authorization for two effective Covid‐19 vaccines from Pfizer‐BioNTech and Moderna. Both vaccines use a novel technology of administering vaccination, namely a lipid nanoparticle‐formulated, nucleoside‐modified mRNA vaccine encoding the spike glycoprotein of SARS‐CoV‐2 for subsequent antigen presentation and immune system activation (1).
ISSN:0926-9959
1468-3083
DOI:10.1111/jdv.17248